Could a daily pill replace growth hormone shots for short children?

NCT ID NCT06948214

Recruiting now Disease control Sponsor: Lumos Pharma Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This phase 3 trial tests an oral medication called LUM-201 in about 150 prepubertal children with growth hormone deficiency who have never been treated before. The study compares the pill to a placebo over 12 months to see if it improves growth rate. The goal is to offer a simpler, daily pill option instead of injections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Lumos Pharma Investigational Site
RECRUITING

Birmingham, Alabama, 35233, United States
Lumos Pharma Investigational Site
RECRUITING

Madera, California, 93636, United States
Lumos Pharma Investigational Site
RECRUITING

Sacramento, California, 95821, United States
Lumos Pharma Investigational Site
RECRUITING

Centennial, Colorado, 80112, United States
Lumos Pharma Investigational Site
RECRUITING

Greenwood Village, Colorado, 80111, United States
Lumos Pharma Investigational Site
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Lumos Pharma Investigational Site
RECRUITING

Hollywood, Florida, 33021, United States
Lumos Pharma Investigational Site
RECRUITING

Miami, Florida, 33155, United States
Lumos Pharma Investigational Site
RECRUITING

Orlando, Florida, 32806, United States
Lumos Pharma Investigational Site
RECRUITING

Tallahassee, Florida, 32308, United States
Lumos Pharma Investigational Site
RECRUITING

Indianapolis, Indiana, 46202, United States
Lumos Pharma Investigational Site
RECRUITING

Iowa City, Iowa, 52242, United States
Lumos Pharma Investigational Site
RECRUITING

New Orleans, Louisiana, 70118, United States
Lumos Pharma Investigational Site
RECRUITING

Minneapolis, Minnesota, 55454, United States
Lumos Pharma Investigational Site
RECRUITING

Kansas City, Missouri, 64108, United States
Lumos Pharma Investigational Site
RECRUITING

Las Vegas, Nevada, 89113, United States
Lumos Pharma Investigational Site
RECRUITING

New Brunswick, New Jersey, 08901, United States
Lumos Pharma Investigational Site
RECRUITING

Staten Island, New York, 10306, United States
Lumos Pharma Investigational Site
RECRUITING

Columbia, South Carolina, 29203, United States
Lumos Pharma Investigational Site
RECRUITING

Amarillo, Texas, 79106, United States
Lumos Pharma Investigational Site
RECRUITING

Corpus Christi, Texas, 78411, United States
Lumos Pharma Investigational Site
RECRUITING

Fort Worth, Texas, 76104, United States
Lumos Pharma Investigational Site
RECRUITING

Charlottesville, Virginia, 22908, United States
Lumos Pharma Investigational Site
RECRUITING

Seattle, Washington, 98105, United States
Lumos Pharma Investigational Site
RECRUITING

Parkville, Victoria, 3052, Australia
Lumos Pharma Investigational Site
RECRUITING

Auckland, 1142, New Zealand
Lumos Pharma Investigational Site
RECRUITING

Wellington, 6242, New Zealand
Lumos Pharma Investigational Site
RECRUITING

London, England, E1 1BB, United Kingdom
Lumos Pharma Investigational Site
RECRUITING

London, England, W1G9AB, United Kingdom

Conditions

Explore the condition pages connected to this study.

GROWTH HORMONE DEFICIENCY (GHD)